https://www.selleckchem.com/products/byl719.html
001) and LVSI(+) ( 0.001) were significantly decreased; fewer patients were with ≥2 intermediate-risk factors (10.5 53.2%, 0.001) so that the rate of adjuvant radiotherapy was reduced (54.2 70.0%, = 0.002). DFS and OS were similar between the NACTS group and PS group ( 0.05). However, for patients with tumor diameter ≥5 cm or SCC ≥5 ng/ml, DFS of the NACTS group was significantly prolonged ( = 0.016, = 0.007). Paclitaxel plus platinum neoadjuvant chemotherapy can reduce adjuvant radiotherapy by decreasing pathological risk
Like
Comment
Share
